|
Market Closed -
Nasdaq
15:57:35 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 0.3985 USD | +4.62% |
|
+1.63% | -70.26% |
| 08-07 | Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 06-08 | Soligenix Applies for Vaccine Development Funding for Bundibugyo Ebola Vaccine | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 8.71M | - | - | - | - | - |
| 70.07B | |||||
| 52.87B | |||||
| 27.02B | - | ||||
| 23.61B | |||||
| 23.38B | - |
- Stock Market
- Stocks
- SNGX Stock
- Charts Soligenix, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
